Loading...
Carmustine — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Carmustine
2025-Q4
Comprehensive analysis of India’s carmustine export trade — suppliers, buyers, prices, routes, and every shipment record.
47
Shipments
$1.26M
Trade Value
11
Suppliers
17
Buyers
17
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/carmustine
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s carmustine trade — 2025-Q4
KEY TAKEAWAY
Carmustine 2025-Q4 exports total $1.3M across 17 countries, with EMCURE PHARMACEUTICALS LTD commanding 62.0% market share.
TOTAL SHIPMENTS
47
2025-Q4
EXPORT VALUE
$1.3M
FOB USD
TOTAL QUANTITY
22.4K
units shipped
INDIAN SUPPLIERS
11
unique exporters
GLOBAL BUYERS
17
unique importers
DESTINATIONS
17
countries
MEDIAN UNIT PRICE
$19.08
per unit
TOP-5 SHARE
99.4%
of total USD
BRANDED SHARE
25.5%
12 shipments
DOSAGE FORMS
7
product types
6 KEY FINDINGS
1
EMCURE PHARMACEUTICALS LTD is India's #1 Carmustine exporter with $783.3K (62.0% market share).→ §5, Indian Supplier Rankings
2
Carmustine reached 17 countries, with Malta as the top destination ($818.3K).→ §4, Global Destination Map
3
Market concentration is high (HHI: 4344) — top 10 suppliers control 100.0% of exports.→ §5, Indian Supplier Rankings
4
88.2% of buyers (15 of 17) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Injection dominates (85.1%) across 7 dosage forms.→ §7, Price Benchmarks
6
17 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 EMCURE PHARMACEUTICALS LTD leads in volume — how do 11 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian carmustine exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Carmustine report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial carmustine trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian carmustine suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Carmustine India trade report
Product scope
Carmustine
All variants merged — branded and generic formulations of carmustine
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
47
Every commercial carmustine trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a v-curve: Oct $328.4K, Nov $207.1K, Dec $728.6K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$328.4K
Oct USD
13 shipments
2
$207.1K
Nov USD
-36.9% MoM
3
$728.6K
Dec USD
+251.8% MoM
4
V-curve
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 36.9% in USD but shipment count kept steady.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $328K, making it the middle month by value.
Fig 3.2 Q4 cumulative USD reached $1.3M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $121K dip in Nov, $521K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Nov’s dip was fully recovered by Dec.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $328K | 13 shipments |
| Nov | $207K | 5 shipments |
| Dec | $729K | 29 shipments |
| Q4 Total | $1.3M | 47 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: Malta held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: EMCURE PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import carmustine from India, how much they buy, and who supplies each market
KEY TAKEAWAY
Malta absorbs 64.7% of India’s 2025-Q4 carmustine trade ($818.3K). Beyond the top 10 destinations, 17 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 7 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 17 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much carmustine India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$122K
9.7% of trade
7 countries · 9 shipments
Europe
$855K
67.6% of trade
6 countries · 30 shipments
Americas
$231K
18.3% of trade
2 countries · 5 shipments
Oceania
$56K
4.4% of trade
2 countries · 3 shipments
Fig 4.1 Malta is the #1 corridor ($818K) — 17 flow arcs from India radiate across 4 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian carmustine it receives (light = low, dark = high). Orange arcs radiate from India to the top 17 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Malta | $818K | 19 | EMCURE PHARMACEUTICALS LTD | $658K | MSN LABORATORIES PVT LTD | $160K | — | — |
| 2 | United States | $231K | 3 | ALEMBIC PHARMACEUTICALS LTD | $207K | MSN LABORATORIES PVT LTD | $24K | — | — |
| 3 | Taiwan | $49K | 1 | THERDOSE PHARMA PVT LTD | $49K | — | — | — | — |
| 4 | Singapore | $41K | 1 | EMCURE PHARMACEUTICALS LTD | $41K | — | — | — | — |
| 5 | Australia | $37K | 2 | EMCURE PHARMACEUTICALS LTD | $37K | — | — | — | — |
| 6 | Bangladesh | $22K | 1 | EMCURE PHARMACEUTICALS LTD | $22K | — | — | — | — |
| 7 | New Zealand | $18K | 1 | EMCURE PHARMACEUTICALS LTD | $18K | — | — | — | — |
| 8 | France | $16K | 1 | INTAS PHARMACEUTICALS LTD | $16K | — | — | — | — |
| 9 | Netherlands | $12K | 4 | INTAS PHARMACEUTICALS LTD | $12K | — | — | — | — |
| 10 | Malaysia | $6K | 2 | THERDOSE PHARMA PVT LTD | $6K | 3S PHARMACEUTICALS INDIA PVT LTD | $77 | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 9.7% of USD — but Malta is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
64.7%
#1 country share
Malta alone
93.1%
Top 5 share
5 of 17 countries
100.0%
Top 15 share
Long tail of 2 countries = 0.0%
HHI 4567
Destination HHI
Highly concentrated
17
Countries served
Global pharma reach from India
7
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
11 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
EMCURE PHARMACEUTICALS LTD ($783.3K, 62.0% share) and ALEMBIC PHARMACEUTICALS LTD ($207.3K) together control 78.4% of India’s 2025-Q4 carmustine trade. The top 5 suppliers hold 99.4%. 11 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian carmustine suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 EMCURE PHARMACEUTICALS LTD leads by $576K over ALEMBIC PHARMACEUTICALS LTD — top 11 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: ALEMBIC PHARMACEUTICALS LTD is #2 by value but #7 by volume.
Fig 5.2 EMCURE PHARMACEUTICALS LTD also leads by shipment count (24) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: ALEMBIC PHARMACEUTICALS LTD moves from #7 by volume to #2 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 11 carmustine suppliers split into strategic segments
KEY TAKEAWAY
3 suppliers (25%) generate 92.9% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 EMCURE PHARMACEUTICALS LTD and ALEMBIC PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 92.9% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LTD | 4 | 3 | $27K |
| 2 | MSN LABORATORIES PVT LTD | 2 | 2 | $184K |
| 3 | AMRS HEALTHCARE PVT LTD | 2 | 1 | $269 |
| 4 | EMCURE PHARMACEUTICALS LTD | 1 | 6 | $783K |
| 5 | ALEMBIC PHARMACEUTICALS LTD | 1 | 1 | $207K |
| 6 | THERDOSE PHARMA PVT LTD | 1 | 2 | $55K |
| 7 | BRUCK PHARMA PVT LTD | 1 | 1 | $4K |
| 8 | CHUZAAR PHARMACEUTICALS PVT LTD | 1 | 1 | $3K |
| 9 | 3S PHARMACEUTICALS INDIA PVT LTD | 1 | 1 | $77 |
| 10 | MBA PHARMACEUTICALS PVT LTD | 1 | 1 | $14 |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the carmustine manufacturing hubs
KEY TAKEAWAY
Sanand and Gujarat together account for $991K of India’s 2025-Q4 carmustine trade.
Fig 5.5 Sanand (1 exporters, $783K) and Gujarat (1 exporters, $207K) are India’s carmustine capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
99.4%
Top 5 share
5 of 11 suppliers
100.0%
Top 10 share
10 of 11 suppliers
92.9%
Top 25% share
3 suppliers = 93% USD
HHI 4344
Supplier HHI
Concentrated
11
Total suppliers
shipped Carmustine in 2025-Q4
10+ cities
Indian hubs
Sanand and Gujarat lead
§5.2 Coming next: 2 exporter deep-dive profiles
Each of the top 2 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | EMCURE PHARMACEUTICALS LTD | $783K |
| #2 | INTAS PHARMACEUTICALS LTD | $27K |
#1
EXPORTER PROFILE #1 OF 2
EMCURE PHARMACEUTICALS LTD
Sanand · India’s #1 carmustine supplier by USD · 2025-Q4
2025-Q4 USD
$783K
62.0% market share
SHIPMENTS
24
avg $33K/ship
COUNTRIES
6
destination markets
BUYERS
7
6 single-sourced
BRANDED
33%
of shipments
DOSAGE FORMS
1
product types
TOP 6 DESTINATIONS
Malta is the #1 market at $658K (84% of trade), followed by Singapore at $41K. 6 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Malta | $658K | 17 | 84.0% |
| 2 | Singapore | $41K | 1 | 5.3% |
| 3 | Australia | $37K | 2 | 4.8% |
| 4 | Bangladesh | $22K | 1 | 2.8% |
| 5 | New Zealand | $18K | 1 | 2.3% |
| 6 | United Kingdom | $6K | 2 | 0.7% |
MONTHLY TREND
Dec was the strongest month, ending the quarter on a high at $514K.
PRODUCT MIX
Injection dominates at 100% of trade. Unknown (0.0%) and others are secondary formulations.
TOP BUYERS · 6/7 LOCKED IN
6 of 7 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| TILLOMED MALTA LTD | Malta | $658K | ⚠ Locked |
| ADVAGEN PTE LTD | Singapore | $41K | ⚠ Locked |
| APOTEX PTY LTD | Australia | $37K | ⚠ Locked |
| RENATA PLC | Bangladesh | $22K | ⚠ Locked |
| ARROTEX PHARMACEUTICAL… | New Zealand | $18K | ⚠ Locked |
| TILLOMED LABORATORIES … | United Kingdom | $6K | ⚠ Locked |
| PHARMADOX HEALTHCARE LTD | Malta | $0 | 2 sup. |
#1
EXPORTER PROFILE #1 OF 2 — TRADE FLOW MAP
EMCURE PHARMACEUTICALS LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 Malta absorbs $658K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
#5
EXPORTER PROFILE #2 OF 2
INTAS PHARMACEUTICALS LTD
Ahmedabad · India’s #5 carmustine supplier by USD · 2025-Q4
2025-Q4 USD
$27K
2.2% market share
SHIPMENTS
8
avg $3K/ship
COUNTRIES
3
destination markets
BUYERS
3
2 single-sourced
BRANDED
0%
of shipments
DOSAGE FORMS
4
product types
TOP 3 DESTINATIONS
France is the #1 market at $16K (58% of trade), followed by Netherlands at $12K. 3 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | France | $16K | 1 | 57.7% |
| 2 | Netherlands | $12K | 4 | 42.1% |
| 3 | Hungary | $57 | 3 | 0.2% |
MONTHLY TREND
Nov peaked at $16K. Dec was the weakest at $163.
PRODUCT MIX
Vial dominates at 99% of trade. powder+vial (0.5%) and Powder are secondary formulations.
TOP BUYERS · 2/2 LOCKED IN
2 of 2 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| Undisclosed buyer | Netherlands | $27K | N/A |
| EUROFINS BIOPHARMA PRO… | Hungary | $43 | ⚠ Locked |
| EUROFINS BIOPHARMA PRO… | Hungary | $14 | ⚠ Locked |
#5
EXPORTER PROFILE #2 OF 2 — TRADE FLOW MAP
INTAS PHARMACEUTICALS LTD — Supplier → Country → Importer
3 destination countries, top 5 importers per country
Fig 5.P2.3 France absorbs $16K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
17 importers across 17 countries — who is buying Indian carmustine and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 16 importers together hold only 97.5% of total USD. 88% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian carmustine. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 TILLOMED MALTA LTD is the #1 importer at $658K (52.1%) — top 16 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 16 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
88%
Single-source
15 buyers rely on exactly 1 Indian supplier
6%
Dual-source
1 buyers use 2 Indian suppliers
6%
Multi-source (3–4)
1 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source carmustine from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| J. KNIPPER & COMPANY | ALEMBIC PHARMACEUTIC… | $207K | $95.958 | Injection |
| NOVADOZ PHARMACEUTICAL… | MSN LABORATORIES PVT… | $24K | $17.832 | Injection |
Malaysia 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| FTA PHARMA SDN BHD | THERDOSE PHARMA PVT … | $6K | $40.091 | Injection |
| FOR THE ORDER OF | 3S PHARMACEUTICALS I… | $77.483 | $15.497 | Injection |
Hungary 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| EUROFINS BIOPHARMA PRO… | INTAS PHARMACEUTICAL… | $42.977 | $0.860 | Powder |
| EUROFINS BIOPHARMA PRO… | INTAS PHARMACEUTICAL… | $13.766 | $0.551 | powder for concentrate for solution for infusion |
Malta 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| TILLOMED MALTA LTD | EMCURE PHARMACEUTICA… | $658K | $91.292 | Injection |
Taiwan 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| DRAGON PHARMACEUTICAL … | THERDOSE PHARMA PVT … | $49K | $121.901 | Injection |
§6.3 Price positioning — top 16 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | TILLOMED MALTA LTD | Malta | $658K | $41K | Premium |
| 2 | J. KNIPPER & COMPANY | United States | $207K | $207K | Premium |
| 3 | PHARMADOX HEALTHCARE… | Malta | $160K | $53K | Premium |
| 4 | DRAGON PHARMACEUTICA… | Taiwan | $49K | $49K | Premium |
| 5 | ADVAGEN PTE LTD | Singapore | $41K | $41K | Premium |
| 6 | APOTEX PTY LTD | Australia | $37K | $19K | Mid |
| 7 | NOVADOZ PHARMACEUTIC… | United States | $24K | $12K | Budget |
| 8 | RENATA PLC | Bangladesh | $22K | $22K | Mid |
| 9 | ARROTEX PHARMACEUTIC… | New Zealand | $18K | $18K | Mid |
| 10 | FTA PHARMA SDN BHD | Malaysia | $6K | $6K | Budget |
| 11 | TILLOMED LABORATORIE… | United Kingdom | $6K | $3K | Budget |
| 12 | DECKAIR CARGO SERVIC… | United Arab Emirates | $3K | $3K | Budget |
| 13 | FOR THE ORDER OF | Malaysia | $77.483 | $77.000 | Budget |
| 14 | EUROFINS BIOPHARMA P… | Hungary | $42.977 | $21.000 | Budget |
| 15 | EUROFINS BIOPHARMA P… | Hungary | $13.766 | $14.000 | Budget |
| 16 | AS PER INVOICE SRI L… | Sri Lanka | $0.956 | $0.0000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 11 × 16 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 EMCURE PHARMACEUTICALS LTD → TILLOMED MALTA LTD is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 11 Indian suppliers; right = top 16 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian carmustine prices vary by supplier, country and dosage form
KEY TAKEAWAY
Carmustine prices span 3514× ($0.098 → $345.47). The coefficient of variation is 1.30. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.098 | Lowest observed unit price |
| P5 | $0.111 | 5th percentile |
| P25 | $0.860 | 25th percentile (Q1) |
| Median | $19.08 | 50th percentile (Q2) |
| P75 | $103.31 | 75th percentile (Q3) |
| P95 | $185.17 | 95th percentile |
| Max | $345.47 | Highest observed unit price |
| Mean | $59.32 | Arithmetic average |
| CV | 130% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 EMCURE PHARMACEUTICALS LTD prices at $103.06/unit vs market median $19.08.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. INTAS PHARMACEUTICALS LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. EMCURE PHARMACEUTICALS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. 3S PHARMACEUTICALS INDIA Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. ALEMBIC PHARMACEUTICALS LTD Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Oct 2025 | EMCURE PHARMACEU… | Singapore | Injection | 120 | $41K | $345.47 | Sterile formulation premium |
| Dec 2025 | EMCURE PHARMACEU… | Bangladesh | Injection | 100 | $22K | $220.63 | Sterile formulation premium |
| Dec 2025 | EMCURE PHARMACEU… | Malta | Injection | 150 | $26K | $176.30 | Sterile formulation premium |
| Dec 2025 | EMCURE PHARMACEU… | Malta | Injection | 300 | $49K | $162.70 | Sterile formulation premium |
| Nov 2025 | EMCURE PHARMACEU… | Malta | Injection | 900 | $140K | $155.15 | Sterile formulation premium |
| Dec 2025 | EMCURE PHARMACEU… | Malta | Injection | 500 | $64K | $128.69 | Sterile formulation premium |
| Oct 2025 | THERDOSE PHARMA … | Taiwan | Injection | 400 | $49K | $121.90 | Sterile formulation premium |
| Dec 2025 | EMCURE PHARMACEU… | Malta | Injection | 3K | $325K | $108.28 | Sterile formulation premium |
| Oct 2025 | MSN LABORATORIES… | Malta | Solution | 232 | $24K | $104.11 | Specialty / small-batch |
| Oct 2025 | MSN LABORATORIES… | Malta | Solution | 1K | $136K | $103.31 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | INTAS PHARMACEUT… | Netherlands | powder+vial | 1K | $101.64 | $0.098 | |
| Dec 2025 | EMCURE PHARMACEU… | Malta | — | 1 | $0.106 | $0.106 | Small sample / trial shipment |
| Dec 2025 | INTAS PHARMACEUT… | Netherlands | powder+vial | 426 | $48.08 | $0.113 | Small sample / trial shipment |
| Dec 2025 | VAMA LIFECARE PV… | Sri Lanka | Injection | 3 | $0.717 | $0.239 | Sterile formulation premium |
| Dec 2025 | VAMA LIFECARE PV… | Sri Lanka | Injection | 1 | $0.239 | $0.239 | Sterile formulation premium |
| Dec 2025 | MBA PHARMACEUTIC… | Pakistan | Injection | 50 | $13.67 | $0.273 | Sterile formulation premium |
| Dec 2025 | INTAS PHARMACEUT… | Hungary | powder for concentrate for solution for infusion | 25 | $13.77 | $0.551 | Sterile formulation premium |
| Dec 2025 | AMRS HEALTHCARE … | Venezuela | lyophilized injection | 357 | $268.80 | $0.753 | Sterile formulation premium |
| Oct 2025 | INTAS PHARMACEUT… | Hungary | Powder | 25 | $21.49 | $0.860 | Small sample / trial shipment |
| Oct 2025 | INTAS PHARMACEUT… | Hungary | Powder | 25 | $21.49 | $0.860 | Small sample / trial shipment |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship carmustine, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Carmustine leaves India through 5+ ports. The top 5 (MUMBAI AIR (SAHAR), AHMEDABAD AIR, HYDERABAD AIR) handle 100.0% of total USD. AIR moves 91% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 MUMBAI AIR (SAHAR) handles $668K — top 5 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 MALTA is the #1 global destination port — top 20 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 91% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$1.3M
100.0% of USD · 91.5% of ships
SEA
$48
0.0% of USD · 8.5% of ships
Fig 8.3 The dominant corridor is MUMBAI AIR (SAHAR) → Air → Europe ($668K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Netherlands is the most concentrated destination (HHI 10000, 1 suppliers). Malta is the most competitive (HHI 6854).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Netherlands (HHI 10,000) is the most concentrated — Malta (HHI 6,854) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 17 of 17 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| TILLOMED MALTA LTD | Malta | EMCURE PHARMACEU… | $658K | 16 | CRITICAL |
| J. KNIPPER & COMPANY | United States | ALEMBIC PHARMACE… | $207K | 1 | HIGH |
| DRAGON PHARMACEUTICA… | Taiwan | THERDOSE PHARMA … | $49K | 1 | MEDIUM |
| ADVAGEN PTE LTD | Singapore | EMCURE PHARMACEU… | $41K | 1 | MEDIUM |
| APOTEX PTY LTD | Australia | EMCURE PHARMACEU… | $37K | 2 | MEDIUM |
| NOVADOZ PHARMACEUTIC… | United States | MSN LABORATORIES… | $24K | 2 | MEDIUM |
| RENATA PLC | Bangladesh | EMCURE PHARMACEU… | $22K | 1 | MEDIUM |
| ARROTEX PHARMACEUTIC… | New Zealand | EMCURE PHARMACEU… | $18K | 1 | MEDIUM |
Conclusion: 15 buyers depend on exactly one Indian supplier, representing $1.1M in trade. 1 are rated CRITICAL — if their sole supplier fails, they have no backup. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| Malta | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Taiwan | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Singapore | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Australia | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Bangladesh | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| New Zealand | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| France | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Malaysia | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Kingdom | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Bosnia and Herzegovina | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Venezuela | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Hungary | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 12 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in Malta | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Netherlands lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Malta (2 suppliers) | This Q | HIGH |
| A6 | Enter United States (2 suppliers) | This Q | MED |
| A8 | Build United States distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for Malta tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Malta | Other | 2 | $818K | +191.9% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | United States | Other | 2 | $231K | +781.9% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Taiwan | Asia | 1 | $49K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Singapore | Asia | 1 | $41K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Australia | Other | 1 | $37K | +3.1% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Bangladesh | Asia | 1 | $22K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | New Zealand | Other | 1 | $18K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | France | Other | 1 | $16K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Netherlands | Other | 1 | $12K | -98.7% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Malaysia | Asia | 2 | $6K | -98.8% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | United Kingdom | Other | 1 | $6K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Bosnia and Herzegovina | Other | 1 | $4K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | United Arab Emirates | Other | 1 | $3K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Venezuela | Other | 1 | $269 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Hungary | Other | 1 | $57 | -68% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 47 2025-Q4 Carmustine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/carmustine
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 47 2025-Q4 carmustine shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian carmustine shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
47
across all regions
TOTAL USD
$1.26M
2025-Q4 FOB value
UNITS
22.4K
tablets, capsules, etc.
SUPPLIERS
11
Indian exporters
BUYERS
17
global importers
COUNTRIES
17
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Asia is the largest region at $122K (9.7%), spanning 7 countries.
11 Indian suppliers shipped to 17 buyers across 17 countries — average shipment value $27K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
7 countries · 9 shipments · $122K · 6 Indian suppliers · 8 buyers
SHIPMENTS
9
USD
$122K
COUNTRIES
7
SUPPLIERS
6
BUYERS
8
HHI
4,752
concentrated
Top 7 destination countries in Asia
1
Taiwan (39.9%)
$49K
2
Singapore (33.9%)
$41K
3
Bangladesh (18.1%)
$22K
4
Malaysia (5.3%)
$6K
5
United Arab Emirates (2.8%)
$3K
6
Pakistan (0.0%)
$13.67
7
Sri Lanka (0.0%)
$0.956
Top 6 Indian suppliers into Asia
1
EMCURE PHARMACEUTICALS LTD
$64K
2
THERDOSE PHARMA PVT LTD
$55K
3
CHUZAAR PHARMACEUTICALS PVT LTD
$3K
4
3S PHARMACEUTICALS INDIA PVT LTD
$77.48
5
MBA PHARMACEUTICALS PVT LTD
$13.67
6
VAMA LIFECARE PVT LTD
$0.956
Top 7 Asia importers
1
DRAGON PHARMACEUTICAL CO LTD · Taiwan
$49K
2
ADVAGEN PTE LTD · Singapore
$41K
3
RENATA PLC · Bangladesh
$22K
4
FTA PHARMA SDN BHD · Malaysia
$6K
5
DECKAIR CARGO SERVICES LLC · United Arab Emirates
$3K
6
FOR THE ORDER OF · Malaysia
$77.48
7
AS PER INVOICE SRI LANKA · Sri Lanka
$0.956
Top 1 dosage forms
1
Injection
$122K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $97K | $32K |
| Nov | 0 | $0.0000 | — |
| Dec | 6 | $26K | $4K |
Shipment register · 9 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — EMCURE PHARMACEUTICALS LTD · 2 shipments · $64K | |||||||||||
| 1 | Oct 2025 | ADVAGEN PTE LTD | Singapore | Injection | 120 | VLS | $345.47 | $41K | AHMEDABAD AIR | SINGAPORE | AIR |
| 2 | Dec 2025 | RENATA PLC | Bangladesh | Injection | 100 | VLS | $220.63 | $22K | AHMEDABAD AIR | DHAKA | AIR |
| SUPPLIER #2 — THERDOSE PHARMA PVT LTD · 2 shipments · $55K | |||||||||||
| 3 | Oct 2025 | DRAGON PHARMACEUTICAL CO LTD | Taiwan | Injection | 400 | NOS | $121.90 | $49K | HYDERABAD AIR | TAIPEI | AIR |
| 4 | Oct 2025 | FTA PHARMA SDN BHD | Malaysia | Injection | 160 | VLS | $40.09 | $6K | HYDERABAD AIR | KUALA LUMPUR - INT'L | AIR |
| SUPPLIER #3 — CHUZAAR PHARMACEUTICALS PVT LTD · 1 shipments · $3K | |||||||||||
| 5 | Dec 2025 | DECKAIR CARGO SERVICES LLC | United Arab Emirates | Injection | 80 | PCS | $42.06 | $3K | DELHI AIR | DUBAI | AIR |
| SUPPLIER #4 — 3S PHARMACEUTICALS INDIA PVT LTD · 1 shipments · $77.48 | |||||||||||
| 6 | Dec 2025 | FOR THE ORDER OF | Malaysia | Injection | 5 | NOS | $15.50 | $77.48 | MUMBAI AIR (SAHAR) | KUALA LUMPUR - INT'L | AIR |
| SUPPLIER #5 — MBA PHARMACEUTICALS PVT LTD · 1 shipments · $13.67 | |||||||||||
| 7 | Dec 2025 | UNLISTED BUYER | Pakistan | Injection | 50 | VLS | $0.273 | $13.67 | DELHI AIR | ISLAMABAD - ISLAMABA | AIR |
| SUPPLIER #6 — VAMA LIFECARE PVT LTD · 2 shipments · $0.956 | |||||||||||
| 8 | Dec 2025 | AS PER INVOICE SRI LANKA | Sri Lanka | Injection | 3 | NOS | $0.239 | $0.717 | MUMBAI AIR (SAHAR) | COLOMBO | AIR |
| 9 | Dec 2025 | AS PER INVOICE SRI LANKA | Sri Lanka | Injection | 1 | NOS | $0.239 | $0.239 | MUMBAI AIR (SAHAR) | COLOMBO | SEA |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
6 countries · 30 shipments · $855K · 4 Indian suppliers · 6 buyers
SHIPMENTS
30
USD
$855K
COUNTRIES
6
SUPPLIERS
4
BUYERS
6
HHI
6,391
concentrated
Top 6 destination countries in Europe
1
Malta (95.7%)
$818K
2
France (1.9%)
$16K
3
Netherlands (1.4%)
$12K
4
United Kingdom (0.7%)
$6K
5
Bosnia and Herzegovina (0.4%)
$4K
6
Hungary (0.0%)
$56.74
Top 4 Indian suppliers into Europe
1
EMCURE PHARMACEUTICALS LTD
$664K
2
MSN LABORATORIES PVT LTD
$160K
3
INTAS PHARMACEUTICALS LTD
$27K
4
BRUCK PHARMA PVT LTD
$4K
Top 5 Europe importers
1
TILLOMED MALTA LTD · Malta
$658K
2
PHARMADOX HEALTHCARE LTD · Malta
$160K
3
TILLOMED LABORATORIES LTD · United Kingdom
$6K
4
EUROFINS BIOPHARMA PRODUCT TESTING · Hungary
$42.98
5
EUROFINS BIOPHARMA PRODUCT TESTIN · Hungary
$13.77
Top 7 dosage forms
1
Injection
$668K
2
Solution
$160K
3
Vial
$27K
4
powder+vial
$149.72
5
Powder
$42.98
6
powder for concentrate for solution for infusion
$13.77
7
Unknown
$0.106
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 6 | $171K | $29K |
| Nov | 5 | $207K | $41K |
| Dec | 19 | $476K | $25K |
Shipment register · 30 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — EMCURE PHARMACEUTICALS LTD · 19 shipments · $664K | |||||||||||
| 1 | Nov 2025 | TILLOMED MALTA LTD | Malta | Injection | 500 | NOS | $103.26 | $52K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 2 | Nov 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 3 | Nov 2025 | TILLOMED MALTA LTD | Malta | Injection | 900 | NOS | $155.15 | $140K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 4 | Nov 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 5 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 150 | NOS | $176.30 | $26K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 6 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 221 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 7 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 300 | NOS | $162.70 | $49K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 8 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 9 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 3.0K | NOS | $108.28 | $325K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 10 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 221 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 11 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 500 | NOS | $128.69 | $64K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 12 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 13 | Dec 2025 | PHARMADOX HEALTHCARE LTD | Malta | 1 | NOS | $0.106 | $0.106 | MUMBAI AIR (SAHAR) | LOUBOMO | SEA | |
| 14 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 1.0K | NOS | $2.61 | $3K | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 15 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 16 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 350 | NOS | $0.935 | $327.25 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 17 | Dec 2025 | TILLOMED MALTA LTD | Malta | Injection | 12 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MALTA | AIR |
| 18 | Dec 2025 | TILLOMED LABORATORIES LTD | United Kingdom | Injection | 2.5K | NOS | $2.28 | $6K | MUMBAI AIR (SAHAR) | LONDON - HEATHROW | AIR |
| 19 | Dec 2025 | TILLOMED LABORATORIES LTD | United Kingdom | Injection | 221 | NOS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | LONDON - HEATHROW | AIR |
| SUPPLIER #2 — MSN LABORATORIES PVT LTD · 2 shipments · $160K | |||||||||||
| 20 | Oct 2025 | PHARMADOX HEALTHCARE LTD | Malta | Solution | 1.3K | NOS | $103.31 | $136K | HYDERABAD AIR | MALTA | AIR |
| 21 | Oct 2025 | PHARMADOX HEALTHCARE LTD | Malta | Solution | 232 | NOS | $104.11 | $24K | HYDERABAD AIR | MALTA | AIR |
| SUPPLIER #3 — INTAS PHARMACEUTICALS LTD · 8 shipments · $27K | |||||||||||
| 22 | Oct 2025 | UNLISTED BUYER | Netherlands | Vial | 598 | VLS | $8.31 | $5K | AHMEDABAD AIR | AMSTERDAM, SCHIPHOL | AIR |
| 23 | Oct 2025 | UNLISTED BUYER | Netherlands | Vial | 889 | VLS | $7.24 | $6K | AHMEDABAD AIR | AMSTERDAM, SCHIPHOL | AIR |
| 24 | Oct 2025 | EUROFINS BIOPHARMA PRODUCT TESTING | Hungary | Powder | 25 | NOS | $0.860 | $21.49 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 25 | Oct 2025 | EUROFINS BIOPHARMA PRODUCT TESTING | Hungary | Powder | 25 | NOS | $0.860 | $21.49 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 26 | Nov 2025 | UNLISTED BUYER | France | Vial | 1.5K | VLS | $10.66 | $16K | AHMEDABAD AIR | PARIS - CHARLES DE G | AIR |
| 27 | Dec 2025 | EUROFINS BIOPHARMA PRODUCT TESTIN | Hungary | powder for concentrate for solution for infusion | 25 | NOS | $0.551 | $13.77 | AHMEDABAD AIR | BUDAPEST, | AIR |
| 28 | Dec 2025 | UNLISTED BUYER | Netherlands | powder+vial | 426 | VLS | $0.113 | $48.08 | MUNDRA SEA | Rotterdam | SEA |
| 29 | Dec 2025 | UNLISTED BUYER | Netherlands | powder+vial | 1.0K | VLS | $0.098 | $101.64 | MUNDRA SEA | Rotterdam | AIR |
| SUPPLIER #4 — BRUCK PHARMA PVT LTD · 1 shipments · $4K | |||||||||||
| 30 | Dec 2025 | UNLISTED BUYER | Bosnia and Herzegovina | Injection | 60 | NOS | $59.73 | $4K | MUMBAI AIR (SAHAR) | SARAJEVO | AIR |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
2 countries · 5 shipments · $231K · 3 Indian suppliers · 3 buyers
SHIPMENTS
5
USD
$231K
COUNTRIES
2
SUPPLIERS
3
BUYERS
3
HHI
8,152
concentrated
Top 2 destination countries in Americas
1
United States (99.9%)
$231K
2
Venezuela (0.1%)
$268.80
Top 3 Indian suppliers into Americas
1
ALEMBIC PHARMACEUTICALS LTD
$207K
2
MSN LABORATORIES PVT LTD
$24K
3
AMRS HEALTHCARE PVT LTD
$268.80
Top 2 Americas importers
1
J. KNIPPER & COMPANY · United States
$207K
2
NOVADOZ PHARMACEUTICALS LLC · United States
$24K
Top 2 dosage forms
1
Injection
$231K
2
lyophilized injection
$268.80
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 2 | $24K | $12K |
| Nov | 0 | $0.0000 | — |
| Dec | 3 | $208K | $69K |
Shipment register · 5 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ALEMBIC PHARMACEUTICALS LTD · 1 shipments · $207K | |||||||||||
| 1 | Dec 2025 | J. KNIPPER & COMPANY | United States | Injection | 2.2K | NOS | $95.96 | $207K | AHMEDABAD AIR | CHICAGO, IL | AIR |
| SUPPLIER #2 — MSN LABORATORIES PVT LTD · 2 shipments · $24K | |||||||||||
| 2 | Oct 2025 | NOVADOZ PHARMACEUTICALS LLC | United States | Injection | 486 | NOS | $19.08 | $9K | HYDERABAD AIR | CHICAGO O'HARE INT'L | AIR |
| 3 | Oct 2025 | NOVADOZ PHARMACEUTICALS LLC | United States | Injection | 832 | NOS | $17.11 | $14K | HYDERABAD AIR | CHICAGO O'HARE INT'L | AIR |
| SUPPLIER #3 — AMRS HEALTHCARE PVT LTD · 2 shipments · $268.80 | |||||||||||
| 4 | Dec 2025 | UNLISTED BUYER | Venezuela | lyophilized injection | 357 | NOS | $0.753 | $268.80 | DELHI AIR | CARACAS | AIR |
| 5 | Dec 2025 | UNLISTED BUYER | Venezuela | Injection | 357 | NOS | $0.0000 | $0.0000 | DELHI AIR | CARACAS | SEA |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
2 countries · 3 shipments · $56K · 1 Indian suppliers · 2 buyers
SHIPMENTS
3
USD
$56K
COUNTRIES
2
SUPPLIERS
1
BUYERS
2
HHI
10,000
concentrated
Top 2 destination countries in Oceania
1
Australia (67.2%)
$37K
2
New Zealand (32.8%)
$18K
Top 1 Indian suppliers into Oceania
1
EMCURE PHARMACEUTICALS LTD
$56K
Top 2 Oceania importers
1
APOTEX PTY LTD · Australia
$37K
2
ARROTEX PHARMACEUTICALS(NZ) LTD · New Zealand
$18K
Top 1 dosage forms
1
Injection
$56K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 2 | $37K | $18K |
| Nov | 0 | $0.0000 | — |
| Dec | 1 | $19K | $19K |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — EMCURE PHARMACEUTICALS LTD · 3 shipments · $56K | |||||||||||
| 1 | Oct 2025 | APOTEX PTY LTD | Australia | Injection | 400 | VLS | $46.17 | $18K | AHMEDABAD AIR | SYDNEY | AIR |
| 2 | Oct 2025 | ARROTEX PHARMACEUTICALS(NZ) LTD | New Zealand | Injection | 400 | VLS | $45.81 | $18K | AHMEDABAD AIR | AUCKLAND | AIR |
| 3 | Dec 2025 | APOTEX PTY LTD | Australia | Injection | 400 | VLS | $47.58 | $19K | AHMEDABAD AIR | SYDNEY | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 11 Indian carmustine exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped carmustine in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | EMCURE PHARMACEUTICALS LTD | SANAND | 24 | $783K | Injection | Oceania, Asia |
| 2 | ALEMBIC PHARMACEUTICALS LTD | GUJARAT | 1 | $207K | Injection | Americas |
| 3 | MSN LABORATORIES PVT LTD | HYDERABAD | 4 | $184K | Solution, Injection | Europe, Americas |
| 4 | THERDOSE PHARMA PVT LTD | PRAGATHI NAGAR | 2 | $55K | Injection | Asia |
| 5 | INTAS PHARMACEUTICALS LTD | AHMEDABAD | 8 | $27K | Vial, Powder, powder for concentrate for solution for infusion | Europe |
| 6 | BRUCK PHARMA PVT LTD | NANI | 1 | $4K | Injection | Europe |
| 7 | CHUZAAR PHARMACEUTICALS PVT LTD | THANE | 1 | $3K | Injection | Asia |
| 8 | AMRS HEALTHCARE PVT LTD | NOIDA | 2 | $268.80 | lyophilized injection, Injection | Americas |
| 9 | 3S PHARMACEUTICALS INDIA PVT LTD | MUMBAI | 1 | $77.48 | Injection | Asia |
| 10 | MBA PHARMACEUTICALS PVT LTD | DELHI | 1 | $13.67 | Injection | Asia |
| 11 | VAMA LIFECARE PVT LTD | MUMBAI | 2 | $0.956 | Injection | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 16 global carmustine importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian carmustine in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | TILLOMED MALTA LTD | Malta | 16 | $658K | EMCURE PHARMACEUTICA… | Injection |
| 2 | J. KNIPPER & COMPANY | United States | 1 | $207K | ALEMBIC PHARMACEUTIC… | Injection |
| 3 | PHARMADOX HEALTHCARE LTD | Malta | 3 | $160K | MSN LABORATORIES PVT… | Solution |
| 4 | DRAGON PHARMACEUTICAL CO LTD | Taiwan | 1 | $49K | THERDOSE PHARMA PVT … | Injection |
| 5 | ADVAGEN PTE LTD | Singapore | 1 | $41K | EMCURE PHARMACEUTICA… | Injection |
| 6 | APOTEX PTY LTD | Australia | 2 | $37K | EMCURE PHARMACEUTICA… | Injection |
| 7 | NOVADOZ PHARMACEUTICALS LLC | United States | 2 | $24K | MSN LABORATORIES PVT… | Injection |
| 8 | RENATA PLC | Bangladesh | 1 | $22K | EMCURE PHARMACEUTICA… | Injection |
| 9 | ARROTEX PHARMACEUTICALS(NZ) LTD | New Zealand | 1 | $18K | EMCURE PHARMACEUTICA… | Injection |
| 10 | FTA PHARMA SDN BHD | Malaysia | 1 | $6K | THERDOSE PHARMA PVT … | Injection |
| 11 | TILLOMED LABORATORIES LTD | United Kingdom | 2 | $6K | EMCURE PHARMACEUTICA… | Injection |
| 12 | DECKAIR CARGO SERVICES LLC | United Arab Emirates | 1 | $3K | CHUZAAR PHARMACEUTIC… | Injection |
| 13 | FOR THE ORDER OF | Malaysia | 1 | $77.48 | 3S PHARMACEUTICALS I… | Injection |
| 14 | EUROFINS BIOPHARMA PRODUCT TESTING | Hungary | 2 | $42.98 | INTAS PHARMACEUTICAL… | Powder |
| 15 | EUROFINS BIOPHARMA PRODUCT TESTIN | Hungary | 1 | $13.77 | INTAS PHARMACEUTICAL… | powder for concentrate for solution for infusion |
| 16 | AS PER INVOICE SRI LANKA | Sri Lanka | 2 | $0.956 | VAMA LIFECARE PVT LTD | Injection |
This report covers 47 2025-Q4 Carmustine shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/carmustine
Talk to our trade analyst
Need a custom carmustine report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/carmustine
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Carmustine product page
Live data, supplier directory, price trends, and trade route analysis